Jiangsu YIMI Bio-tech Co Ltd, which is based in Taizhou Medical High-tech Zone, also known as Gaogang district, in Taizhou, East China's Jiangsu province, was recently granted a US invention patent for its liquid collection device.
This signified that the company has made breakthroughs in developing intellectual property, as the strict approval standards and low authorization rate made the US patent valuable.
Founded in 2017, the company focuses on the collection and preservation of biological samples, developing molecular diagnostic technology and cell gene therapy technology.
An exterior view of Jiangsu YIMI Bio-tech Co Ltd. [Photo/cmc.gov.cn]
The company obtained the IP management system certification in 2020 and has established a standardized IP management system.
To date, the company has applied for 50 patents, including an international one, four domestic invention patents, 31 utility model patents, and two design patents.
Devoted to fields in human health prevention and precision treatment, the company has expanded to overseas markets including the US, Australia, Japan, and South Korea.